Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Country | United States |
Founded | 2009 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 33 |
CEO | Dr. Yuval Cohen Ph.D. |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts 02062 United States | |
Phone | 617-963-0103 |
Website | corbuspharma.com |
Stock Details
Ticker Symbol | CRBP |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001595097 |
CUSIP Number | 21833P103 |
ISIN Number | US21833P3010 |
Employer ID | 46-4348039 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Mar 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Mar 12, 2024 | 10-K | Annual Report |
Mar 12, 2024 | 8-K | Current Report |
Feb 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |